Pat Whitworth, MD

Dr. Whitworth on the Importance of Additional HER2 Subtyping

December 10th 2015

Pat Whitworth, MD, medical oncologist at the Nashville Breast Center, discusses the prospective neo-adjuvant NBRST study, which looked at BluePrint functional subtyping versus conventional immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH) in breast tumors.